RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease

Stephen J. Gold, Chau V. Hoang, Bryan W. Potts, Gregory Porras, Elsa Pioli, Woo Kim Ki, Agnes Nadjar, Chuan Qin, Gerald J. LaHoste, Qin Li, Bernard H. Bioulac, Jeffrey L. Waugh, Eugenia Gurevich, Rachael L. Neve, Erwan Bezard

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Chronic L-dopa treatment of Parkinson's disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID), mediated by dopamine (DA) receptors. RGS9-2 is a GTPase accelerating protein that inhibits DA D2 receptor-activated G proteins. Herein, we assess the functional role of RGS9-2 on LID. In monkeys, Western blot analysis of striatal extracts shows that RGS9-2 levels are not altered by MPTP-induced DA denervation and/or chronic L-dopa administration. In MPTP monkeys with LID, striatal RGS9-2 overexpression - achieved by viral vector injection into the striatum - diminishes the involuntary movement intensity without lessening the anti-parkinsonian effects of the D1/D2 receptor agonist L-dopa. In contrasts, in these animals, striatal RGS9-2 overexpression diminishes both the involuntary movement intensity and the anti-parkinsonian effects of the D2/D3 receptor agonist ropinirole. In unilaterally 6-OHDA-lesioned rats with LID, we show that the time course of viral vector-mediated striatal RGS9-2 overexpression parallels the time course of improvement of L-dopa-induced involuntary movements. We also find that unilateral 6-OHDA-lesioned RGS9-/- mice are more susceptible to L-dopa-induced involuntary movements than unilateral 6-OHDA-lesioned RGS9+/+ mice, albeit the rotational behavior - taken as an index of the anti-parkinsonian response - is similar between the two groups of mice. Together, these findings suggest that RGS9-2 plays a pivotal role in LID pathophysiology. However, the findings also suggest that increasing RGS9-2 expression and/or function in PD patients may only be a suitable therapeutic strategy to control involuntary movements induced by nonselective DA agonist such as L-dopa.

Original languageEnglish (US)
Pages (from-to)14338-14348
Number of pages11
JournalJournal of Neuroscience
Volume27
Issue number52
DOIs
StatePublished - Dec 26 2007

Fingerprint

Dyskinesias
Parkinsonian Disorders
Levodopa
Corpus Striatum
Oxidopamine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Haplorhini
Parkinson Disease
Dopamine D2 Receptors
GTP Phosphohydrolases
Dopamine Agonists
Dopamine Receptors
Denervation
GTP-Binding Proteins
Dopamine
Western Blotting
Injections

Keywords

  • Dopamine receptor
  • Dyskinesia
  • Knock-out mouse
  • Monkey
  • Parkinson's disease
  • RGS proteins

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Gold, S. J., Hoang, C. V., Potts, B. W., Porras, G., Pioli, E., Ki, W. K., ... Bezard, E. (2007). RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. Journal of Neuroscience, 27(52), 14338-14348. https://doi.org/10.1523/JNEUROSCI.4223-07.2007

RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. / Gold, Stephen J.; Hoang, Chau V.; Potts, Bryan W.; Porras, Gregory; Pioli, Elsa; Ki, Woo Kim; Nadjar, Agnes; Qin, Chuan; LaHoste, Gerald J.; Li, Qin; Bioulac, Bernard H.; Waugh, Jeffrey L.; Gurevich, Eugenia; Neve, Rachael L.; Bezard, Erwan.

In: Journal of Neuroscience, Vol. 27, No. 52, 26.12.2007, p. 14338-14348.

Research output: Contribution to journalArticle

Gold, SJ, Hoang, CV, Potts, BW, Porras, G, Pioli, E, Ki, WK, Nadjar, A, Qin, C, LaHoste, GJ, Li, Q, Bioulac, BH, Waugh, JL, Gurevich, E, Neve, RL & Bezard, E 2007, 'RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease', Journal of Neuroscience, vol. 27, no. 52, pp. 14338-14348. https://doi.org/10.1523/JNEUROSCI.4223-07.2007
Gold, Stephen J. ; Hoang, Chau V. ; Potts, Bryan W. ; Porras, Gregory ; Pioli, Elsa ; Ki, Woo Kim ; Nadjar, Agnes ; Qin, Chuan ; LaHoste, Gerald J. ; Li, Qin ; Bioulac, Bernard H. ; Waugh, Jeffrey L. ; Gurevich, Eugenia ; Neve, Rachael L. ; Bezard, Erwan. / RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. In: Journal of Neuroscience. 2007 ; Vol. 27, No. 52. pp. 14338-14348.
@article{c08a1968c2f2474a93e5e118e0e80dad,
title = "RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease",
abstract = "Chronic L-dopa treatment of Parkinson's disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID), mediated by dopamine (DA) receptors. RGS9-2 is a GTPase accelerating protein that inhibits DA D2 receptor-activated G proteins. Herein, we assess the functional role of RGS9-2 on LID. In monkeys, Western blot analysis of striatal extracts shows that RGS9-2 levels are not altered by MPTP-induced DA denervation and/or chronic L-dopa administration. In MPTP monkeys with LID, striatal RGS9-2 overexpression - achieved by viral vector injection into the striatum - diminishes the involuntary movement intensity without lessening the anti-parkinsonian effects of the D1/D2 receptor agonist L-dopa. In contrasts, in these animals, striatal RGS9-2 overexpression diminishes both the involuntary movement intensity and the anti-parkinsonian effects of the D2/D3 receptor agonist ropinirole. In unilaterally 6-OHDA-lesioned rats with LID, we show that the time course of viral vector-mediated striatal RGS9-2 overexpression parallels the time course of improvement of L-dopa-induced involuntary movements. We also find that unilateral 6-OHDA-lesioned RGS9-/- mice are more susceptible to L-dopa-induced involuntary movements than unilateral 6-OHDA-lesioned RGS9+/+ mice, albeit the rotational behavior - taken as an index of the anti-parkinsonian response - is similar between the two groups of mice. Together, these findings suggest that RGS9-2 plays a pivotal role in LID pathophysiology. However, the findings also suggest that increasing RGS9-2 expression and/or function in PD patients may only be a suitable therapeutic strategy to control involuntary movements induced by nonselective DA agonist such as L-dopa.",
keywords = "Dopamine receptor, Dyskinesia, Knock-out mouse, Monkey, Parkinson's disease, RGS proteins",
author = "Gold, {Stephen J.} and Hoang, {Chau V.} and Potts, {Bryan W.} and Gregory Porras and Elsa Pioli and Ki, {Woo Kim} and Agnes Nadjar and Chuan Qin and LaHoste, {Gerald J.} and Qin Li and Bioulac, {Bernard H.} and Waugh, {Jeffrey L.} and Eugenia Gurevich and Neve, {Rachael L.} and Erwan Bezard",
year = "2007",
month = "12",
day = "26",
doi = "10.1523/JNEUROSCI.4223-07.2007",
language = "English (US)",
volume = "27",
pages = "14338--14348",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "52",

}

TY - JOUR

T1 - RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease

AU - Gold, Stephen J.

AU - Hoang, Chau V.

AU - Potts, Bryan W.

AU - Porras, Gregory

AU - Pioli, Elsa

AU - Ki, Woo Kim

AU - Nadjar, Agnes

AU - Qin, Chuan

AU - LaHoste, Gerald J.

AU - Li, Qin

AU - Bioulac, Bernard H.

AU - Waugh, Jeffrey L.

AU - Gurevich, Eugenia

AU - Neve, Rachael L.

AU - Bezard, Erwan

PY - 2007/12/26

Y1 - 2007/12/26

N2 - Chronic L-dopa treatment of Parkinson's disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID), mediated by dopamine (DA) receptors. RGS9-2 is a GTPase accelerating protein that inhibits DA D2 receptor-activated G proteins. Herein, we assess the functional role of RGS9-2 on LID. In monkeys, Western blot analysis of striatal extracts shows that RGS9-2 levels are not altered by MPTP-induced DA denervation and/or chronic L-dopa administration. In MPTP monkeys with LID, striatal RGS9-2 overexpression - achieved by viral vector injection into the striatum - diminishes the involuntary movement intensity without lessening the anti-parkinsonian effects of the D1/D2 receptor agonist L-dopa. In contrasts, in these animals, striatal RGS9-2 overexpression diminishes both the involuntary movement intensity and the anti-parkinsonian effects of the D2/D3 receptor agonist ropinirole. In unilaterally 6-OHDA-lesioned rats with LID, we show that the time course of viral vector-mediated striatal RGS9-2 overexpression parallels the time course of improvement of L-dopa-induced involuntary movements. We also find that unilateral 6-OHDA-lesioned RGS9-/- mice are more susceptible to L-dopa-induced involuntary movements than unilateral 6-OHDA-lesioned RGS9+/+ mice, albeit the rotational behavior - taken as an index of the anti-parkinsonian response - is similar between the two groups of mice. Together, these findings suggest that RGS9-2 plays a pivotal role in LID pathophysiology. However, the findings also suggest that increasing RGS9-2 expression and/or function in PD patients may only be a suitable therapeutic strategy to control involuntary movements induced by nonselective DA agonist such as L-dopa.

AB - Chronic L-dopa treatment of Parkinson's disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID), mediated by dopamine (DA) receptors. RGS9-2 is a GTPase accelerating protein that inhibits DA D2 receptor-activated G proteins. Herein, we assess the functional role of RGS9-2 on LID. In monkeys, Western blot analysis of striatal extracts shows that RGS9-2 levels are not altered by MPTP-induced DA denervation and/or chronic L-dopa administration. In MPTP monkeys with LID, striatal RGS9-2 overexpression - achieved by viral vector injection into the striatum - diminishes the involuntary movement intensity without lessening the anti-parkinsonian effects of the D1/D2 receptor agonist L-dopa. In contrasts, in these animals, striatal RGS9-2 overexpression diminishes both the involuntary movement intensity and the anti-parkinsonian effects of the D2/D3 receptor agonist ropinirole. In unilaterally 6-OHDA-lesioned rats with LID, we show that the time course of viral vector-mediated striatal RGS9-2 overexpression parallels the time course of improvement of L-dopa-induced involuntary movements. We also find that unilateral 6-OHDA-lesioned RGS9-/- mice are more susceptible to L-dopa-induced involuntary movements than unilateral 6-OHDA-lesioned RGS9+/+ mice, albeit the rotational behavior - taken as an index of the anti-parkinsonian response - is similar between the two groups of mice. Together, these findings suggest that RGS9-2 plays a pivotal role in LID pathophysiology. However, the findings also suggest that increasing RGS9-2 expression and/or function in PD patients may only be a suitable therapeutic strategy to control involuntary movements induced by nonselective DA agonist such as L-dopa.

KW - Dopamine receptor

KW - Dyskinesia

KW - Knock-out mouse

KW - Monkey

KW - Parkinson's disease

KW - RGS proteins

UR - http://www.scopus.com/inward/record.url?scp=37549025843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549025843&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.4223-07.2007

DO - 10.1523/JNEUROSCI.4223-07.2007

M3 - Article

VL - 27

SP - 14338

EP - 14348

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 52

ER -